Search

everythinglearnresearchcommunity

for

Search:↓

A user bought questionable RU58841 powder from AliExpress and seeks a way to test its composition in Europe. Another user suggests using Janoshik for testing.

A user discusses switching from RU58841 to Pyrilutamide due to side effects like fatigue, brain fog, and elevated heart rate. They have used dutasteride, finasteride, and minoxidil, and are seeking safer alternatives.

Topical finasteride results in plasma levels 100 times lower than oral finasteride, potentially reducing systemic side effects. Users report similar efficacy with fewer side effects, suggesting a preference for topical application.

A user shared their positive experience with the Omnilux Red Light mask for skin and potential hair benefits, while also using Minoxidil, Dutasteride, and RU58841. They recommend the mask for those interested in skincare and red light therapy, despite being unsure of its effectiveness for hair growth.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

Long-term use of finasteride and dutasteride may be linked to health risks like fatty liver disease, insulin resistance, type 2 diabetes, dry eye disease, and potential kidney disease. Some users believe the risks are low and the medications are generally safe.

Switching from finasteride to dutasteride for hair loss treatment. Dutasteride is suggested as a more effective alternative.

Anti-androgens like Finasteride, Dutasteride, Metformin, and Topical Spironolactone cause hairline recession and increased cholesterol levels. The hairline recovers after stopping the drugs.

The conversation discusses sourcing pyrilutamide from China for hair loss treatment, highlighting its potency compared to other AR antagonists like bicalutamide and RU58841. The user expresses interest in trying pyrilutamide despite mixed results in clinical trials.

The conversation discusses the anticipation for updates on GT20029, a potential hair loss treatment. Users also mention using Minoxidil, finasteride, and RU58841.

The conversation discusses using finasteride, dutasteride, minoxidil, cialis, and metformin to protect hair and health. Some users caution against self-prescribing these drugs due to potential risks and complications.

A user found a successful hair loss treatment using a combination of finasteride, dutasteride, minoxidil, and RU58841. They plan to switch to a purely topical regimen with finasteride, RU58841, and minoxidil.

Blocking the Mitochondrial pyruvate carrier and using aldose reductase inhibitors like Indian gooseberry and berberine may help with hair growth. Magnesium can also be added to increase NADPH.

Scube3 trials have not started yet. Treatments discussed include Minoxidil, finasteride, and RU58841.

Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.

Dr. Bloxham's 9-month update on FUT scar revision with Verteporfin shows promising results. Excitement is high for FUE, which appears highly effective based on Dr. Barghouthi's findings.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also mentions an update on Dr. Bloxham's Verteporfin treatment.

Switching from finasteride to dutasteride can reduce scalp DHT levels more effectively. The discussion includes using minoxidil, finasteride, and RU58841 for hair loss treatment.

The conversation discusses the effectiveness of different doses of Dutasteride (Dut) in reducing scalp DHT levels. It suggests that 1mg and 1.5mg doses would reduce scalp DHT by amounts between 51% and 79%.

The conversation discusses potential new treatments for androgenetic alopecia (AGA), including verteporfin, pyrilutamide, and hair cloning. There is optimism about scientific advancements providing alternatives to minoxidil and finasteride.

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

The user discusses using Minoxidil for hair loss and is considering RU58841 to reduce excessive oil production. They seek advice on RU58841's effectiveness in blocking sebum production.

The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.

The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.

Topical bicalutamide is discussed as a potential hair loss treatment. Other treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses concerns about Scube3's effectiveness and potential cancer link. It questions whether Scube3 can regrow hair and how well it works according to researchers.

Dutasteride is shown to be significantly more effective than finasteride for treating male androgenic alopecia. Users discuss the difficulty of obtaining dutasteride in some countries and share personal experiences with its effectiveness and side effects.

Many celebrities and athletes likely use hair loss treatments like Minoxidil and Finasteride. Despite their effectiveness, only a small percentage of the general population uses these treatments.

Melatonin is being discussed as a potential treatment for hair loss, with questions about its effectiveness and whether it should be used topically or orally. No specific conclusions or personal experiences were shared.

NMN shows promise in promoting hair growth by reducing oxidative stress and weakening androgens. It may be a beneficial addition to hair loss treatments like Minoxidil and Finasteride.